MAPK1 and Hepatic fibrosis: JHQ reduced the expression of CXCL8, MAPK1, AKT1, SRC, VEGFA, and IL-6 via EGFR tyrosine kinase inhibitor resistance, Kaposi sarcoma-associated herpesvirus infection, and human cytomegalovirus infection signaling pathways, thereby restricting the liver inflammation, neoangiogenesis, and activated HSCs in liver fibrosis.